News

Gilead pays USD 50 mln to cooperate with Tango Therapeutics startup

Expand

19.11.2018

Gilead and Tango Therapeutics join forces in the immune-oncology sector.The agreement they conducted opens up a possibility for Gilead to acquire the worldwide rights to five inventions owned by Tango.

Tango Therapeutics is a startup backed up by Third Rock Ventures, using CRISPR and other tools to find synthetic lethal gene pairs.Some 12 months ago, Barbara Weber - the CEO of Tango - encouraged potential partners to initiate talks with the company through highlighting its accomplishments.Now, Gilead signed an agreement to give a new impetus to certain projects by Tango, while the latter company still retains full rights to their flagship programs, granting Gilead with an option for acquiring 5 new targets.

Details concerning this cooperation have yet to be disclosed, while Gilead expresses its interest in the research effort of Tango on immune evasion, e.g. with regard to tumour cells that become invisible to one's immune system.Tango believes that it is possible to suppress the phenomenon of using cloaking strategies by tumour cells (thus facilitating the attack of one's organism) through inhibiting relevant signals.

Source: fiercebiotech.com

ASK ABOUT AN OFFER
Feel free to contact us.

Company

Phone: +48 71 725 34 10
e-mail: office@startitfund.pl

Office address
ul. E. Kwiatkowskiego 4, 52-326 Wrocław, Poland

© 2019 - Grupa Kapitałowa Startit Fund | All rights reserved.

Made in: avangardo.eu

Important: I hereby confirm that I have read the Privacy Policy and Cookies Policy of Startit Fund Sp. z o.o. [Ltd.] company
Join us!